Dendritic cells and cancer: From biology to therapeutic intervention

Ben Wylie, Christophe Macri, Justine D. Mintern, Jason Waithman

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Inducing effective anti-tumor immunity has become a major therapeutic strategy against cancer. Dendritic cells (DC) are a heterogenous population of antigen presenting cells that infiltrate tumors. While DC play a critical role in the priming and maintenance of local immunity, their functions are often diminished, or suppressed, by factors encountered in the tumor microenvironment. Furthermore, DC populations with immunosuppressive activities are also recruited to tumors, limiting T cell infiltration and promoting tumor growth. Anti-cancer therapies can impact the function of tumor-associated DC and/or alter their phenotype. Therefore, the design of effective anti-cancer therapies for clinical translation should consider how best to boost tumor-associated DC function to drive anti-tumor immunity. In this review, we discuss the different subsets of tumor-infiltrating DC and their role in anti-tumor immunity. Moreover, we describe strategies to enhance DC function within tumors and harness these cells for effective tumor immunotherapy.

Original languageEnglish
Article number521
JournalCancers
Volume11
Issue number4
DOIs
Publication statusPublished - 1 Apr 2019

Fingerprint

Dendritic Cells
Neoplasms
Therapeutics
Immunity
Tumor Microenvironment
Antigen-Presenting Cells
Immunosuppressive Agents
Immunotherapy
Population
Maintenance
T-Lymphocytes
Phenotype

Cite this

Wylie, Ben ; Macri, Christophe ; Mintern, Justine D. ; Waithman, Jason. / Dendritic cells and cancer : From biology to therapeutic intervention. In: Cancers. 2019 ; Vol. 11, No. 4.
@article{82d062f48a7c4cd3a93290166319c7d7,
title = "Dendritic cells and cancer: From biology to therapeutic intervention",
abstract = "Inducing effective anti-tumor immunity has become a major therapeutic strategy against cancer. Dendritic cells (DC) are a heterogenous population of antigen presenting cells that infiltrate tumors. While DC play a critical role in the priming and maintenance of local immunity, their functions are often diminished, or suppressed, by factors encountered in the tumor microenvironment. Furthermore, DC populations with immunosuppressive activities are also recruited to tumors, limiting T cell infiltration and promoting tumor growth. Anti-cancer therapies can impact the function of tumor-associated DC and/or alter their phenotype. Therefore, the design of effective anti-cancer therapies for clinical translation should consider how best to boost tumor-associated DC function to drive anti-tumor immunity. In this review, we discuss the different subsets of tumor-infiltrating DC and their role in anti-tumor immunity. Moreover, we describe strategies to enhance DC function within tumors and harness these cells for effective tumor immunotherapy.",
keywords = "Cancer, Checkpoint blockade, DC-based therapy, Immunosuppression, Immunotherapy, Novel therapies, Tumor-associated dendritic cells",
author = "Ben Wylie and Christophe Macri and Mintern, {Justine D.} and Jason Waithman",
year = "2019",
month = "4",
day = "1",
doi = "10.3390/cancers11040521",
language = "English",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI AG",
number = "4",

}

Dendritic cells and cancer : From biology to therapeutic intervention. / Wylie, Ben; Macri, Christophe; Mintern, Justine D.; Waithman, Jason.

In: Cancers, Vol. 11, No. 4, 521, 01.04.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dendritic cells and cancer

T2 - From biology to therapeutic intervention

AU - Wylie, Ben

AU - Macri, Christophe

AU - Mintern, Justine D.

AU - Waithman, Jason

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Inducing effective anti-tumor immunity has become a major therapeutic strategy against cancer. Dendritic cells (DC) are a heterogenous population of antigen presenting cells that infiltrate tumors. While DC play a critical role in the priming and maintenance of local immunity, their functions are often diminished, or suppressed, by factors encountered in the tumor microenvironment. Furthermore, DC populations with immunosuppressive activities are also recruited to tumors, limiting T cell infiltration and promoting tumor growth. Anti-cancer therapies can impact the function of tumor-associated DC and/or alter their phenotype. Therefore, the design of effective anti-cancer therapies for clinical translation should consider how best to boost tumor-associated DC function to drive anti-tumor immunity. In this review, we discuss the different subsets of tumor-infiltrating DC and their role in anti-tumor immunity. Moreover, we describe strategies to enhance DC function within tumors and harness these cells for effective tumor immunotherapy.

AB - Inducing effective anti-tumor immunity has become a major therapeutic strategy against cancer. Dendritic cells (DC) are a heterogenous population of antigen presenting cells that infiltrate tumors. While DC play a critical role in the priming and maintenance of local immunity, their functions are often diminished, or suppressed, by factors encountered in the tumor microenvironment. Furthermore, DC populations with immunosuppressive activities are also recruited to tumors, limiting T cell infiltration and promoting tumor growth. Anti-cancer therapies can impact the function of tumor-associated DC and/or alter their phenotype. Therefore, the design of effective anti-cancer therapies for clinical translation should consider how best to boost tumor-associated DC function to drive anti-tumor immunity. In this review, we discuss the different subsets of tumor-infiltrating DC and their role in anti-tumor immunity. Moreover, we describe strategies to enhance DC function within tumors and harness these cells for effective tumor immunotherapy.

KW - Cancer

KW - Checkpoint blockade

KW - DC-based therapy

KW - Immunosuppression

KW - Immunotherapy

KW - Novel therapies

KW - Tumor-associated dendritic cells

UR - http://www.scopus.com/inward/record.url?scp=85065419018&partnerID=8YFLogxK

U2 - 10.3390/cancers11040521

DO - 10.3390/cancers11040521

M3 - Article

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 4

M1 - 521

ER -